Dose-dependency of resveratrol in providing health benefits

Dose-Response

Volumn 8, Issue 4, 2010, Pages 478-500

  Mukherjee, Subhendu ^a   Dudley, Jocelyn I ^a   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649436142     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.09-015.Mukherjee     Document Type: Review

References (118)

1. Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai S, Rice-Evans C and Spencer J P. 2006. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br J Nutr 96:62-70.
2. Acquaviva A R, Campisi A, Sorrenti V, Giacomo C, Barcellona M.L, Avitabile M, Vanella A. 2006. Antioxidant Activity and Protective Effect on DNA Cleavage of Resveratrol Journal of Food Science 67:137-141.
3. Aggarwal B B, Bhardwaj A, Aggarwal R S, Seeram N P, Shishodia S and Takada Y. 2004. Role of resver-atrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783-2840.
4. Aggarwal B B, Shishodia S, Sandur S K, Pandey M K and Sethi G. 2006. Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605-1621.
5. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M and Arichi S. 1982. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull (Tokyo) 30:1766-1770.
6. Athar M, Back J H, Tang X, Kim K H, Kopelovich L, Bickers D R and Kim A L. 2007. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274-283.
7. Atten M J, Godoy-Romero E, Attar B M, Milson T, Zopel M and Holian O. 2005. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 23:111-119.
8. Baur J A, Pearson K J, Price N L, Jamieson H A, Lerin C, Kalra A, Prabhu V V, Allard J S, Lopez-Lluch G, Lewis K, Pistell P J, Poosala S, Becker K G, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein K W, Spencer R G, Lakatta E G, Le Couteur D, Shaw R J, Navas P, Puigserver P, Ingram D K, de Cabo R and Sinclair D A. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
9. Baur J A and Sinclair D A. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506.
10. Benitez D A, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero P M and Castellon E A. 2007. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28:282-293.
11. Bertelli A, Falchi M, Dib B, Pini E, Mukherjee S and Das D K. 2008. Analgesic resveratrol? Antioxid Redox Signal 10:403-404.
12. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair A S, Shishodia S and Aggarwal B B. 2007. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated anti-apoptotic and cell survival gene products in human multiple myeloma cells. Blood 109:2293-2302.
13. Bhat K P and Pezzuto J M. 2001. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 61:6137-6144.
14. Borra M T, Smith B C and Denu J M. 2005. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187-17195.
15. Boyer R F, Clark H M and LaRoche A P. 1988. Reduction and release of ferritin iron by plant phe-nolics. J Inorg Biochem 32:171-181.
16. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argiles J M and Lopez-Soriano F J. 2007. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144-148.
17. Caddeo C, Teskac K, Sinico C and Kristl J. 2008. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 363:183-191.
18. Cadenas S and Barja G. 1999. Resveratrol, melatonin, vitamin E, and PBN protect against renal oxida-tive DNA damage induced by the kidney carcinogen KBrO3. Free Radic Biol Med 26:1531-1537.
19. Candelario-Jalil E, de Oliveira A C, Graf S, Bhatia H S, Hull M, Munoz E and Fiebich B L. 2007. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4:25.
20. Cavallaro A, Ainis T, Bottari C and Fimiani V. 2003. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res 52:555-562.
21. Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet G V and Comi P. 2007. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74:1568-1574.
22. Chan JY K M. 2000. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta. 1517:19-26.
23. Crowell J A, Korytko P J, Morrissey R L, Booth T D and Levine B S. 2004. Resveratrol-associated renal toxicity. Toxicol Sci 82:614-619.
24. Das D K and Maulik N. 2006. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 6:36-47.
25. Das S, Alagappan V K, Bagchi D, Sharma H S, Maulik N and Das D K. 2005a. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 42:281-289.
26. Das S, Cordis G A, Maulik N and Das D K. 2005b. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol 288:H328-335.
27. Das S, Falchi M, Bertelli A, Maulik N and Das D K. 2006a. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung 56:700-706.
28. Das S, Fraga C G and Das D K. 2006b. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic Res 40:1066-1075.
29. Das S, Tosaki A, Bagchi D, Maulik N and Das D K. 2006c. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317:980-988.
30. Dekkers D H, Bezstarosti K, Gurusamy N, Luijk K, Verhoeven A J, Rijkers E J, Demmers J A, Lamers J M, Maulik N and Das D K. 2008. Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. J Cell Mol Med 12:1677-1689.
31. Dong H H and Ren H L. 2004. New progression in the study of protective properties of resveratrol in anticardiovascular disease. Bratisl Lek Listy 105:225-229.
32. Dore S. 2002. Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer's disease. Free Radic Biol Med 32:1276-1282.
33. Dudley J, Das S, Mukherjee S and Das D K. 2008a. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem.
34. Dudley J I, Lekli I, Mukherjee S, Das M, Bertelli A A and Das D K. 2008b. Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56:9362-9373.
35. El-Mowafy A M and White R E. 1999. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett 451:63-67.
36. Evans A R, Limp-Foster M and Kelley M R. 2000. Going APE over ref-1. Mutat Res 461:83-108.
37. Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Vercauteren J, Belloc F, Billiard C, Dupouy M, Thiolat D, Kolb J P, Marit G, Reiffers J and Mossalayi M D. 2002. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 23:1327-1333.
38. Frankel E N, Waterhouse A L and Kinsella J E. 1993. Inhibition of human LDL oxidation by resvera-trol. Lancet 341:1103-1104.
39. Fremont L, Belguendouz L and Delpal S. 1999. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64:2511-2521.
40. Fukuda S, Kaga S, Zhan L, Bagchi D, Das D K, Bertelli A and Maulik N. 2006. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44:43-49.
41. Fukuhara K and Miyata N. 1998. Resveratrol as a new type of DNA-cleaving agent. Bioorg Med Chem Lett 8:3187-3192.
42. Griswold A J, Chang K T, Runko A P, Knight M A and Min K T. 2008. Sir2 mediates apoptosis through JNK-dependent pathways in Drosophila. Proc Natl Acad Sci U S A 105:8673-8678.
43. Gruber J, Tang S Y and Halliwell B. 2007. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y Acad Sci 1100:530-542.
44. Guarente L. 2007. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 72:483-488.
45. Gurusamy N, Malik G, Gorbunov N V and Das D K. 2007. Redox activation of Ref-1 potentiates cell survival following myocardial ischemia reperfusion injury. Free Radic Biol Med 43:397-407.
46. Harper C E, Patel B B, Wang J, Arabshahi A, Eltoum I A and Lamartiniere C A. 2007. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28:1946-1953.
47. Hattori R, Otani H, Maulik N and Das D K. 2002. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282:H1988-1995.
48. Hebbar V, Shen G, Hu R, Kim B R, Chen C, Korytko P J, Crowell J A, Levine B S and Kong A N. 2005. Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299-2314.
49. Hennessy B T, Smith D L, Ram P T, Lu Y and Mills G B. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004.
50. Howitz K T, Bitterman K J, Cohen H Y, Lamming D W, Lavu S, Wood J G, Zipkin R E, Chung P, Kisielewski A, Zhang L L, Scherer B and Sinclair D A. 2003. Small molecule activators of sirtu-ins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
51. Huang R P and Adamson E D. 1993. Characterization of the DNA-binding properties of the early growth response-1 (Egr-1) transcription factor: evidence for modulation by a redox mechanism. DNA Cell Biol 12:265-273.
52. Hwang J T, Kwak D W, Lin S K, Kim H M, Kim Y M and Park O J. 2007. Resveratrol induces apopto-sis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci 1095:441-448.
53. Imamura G, Bertelli A A, Bertelli A, Otani H, Maulik N and Das D K. 2002. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 282:H1996-2003.
54. Iwasaki K, Mackenzie E L, Hailemariam K, Sakamoto K and Tsuji Y. 2006. Hemin-mediated regulation of an antioxidant-responsive element of the human ferritin H gene and role of Ref-1 during erythroid differentiation of K562 cells. Mol Cell Biol 26:2845-2856.
55. Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W, Fong H H, Farnsworth N R, Kinghorn A D, Mehta R G, Moon R C and Pezzuto J M. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
56. Jayatilake G S, Jayasuriya H, Lee E S, Koonchanok N M, Geahlen R L, Ashendel C L, McLaughlin J L and Chang C J. 1993. Kinase inhibitors from Polygonum cuspidatum. J Nat Prod 56:1805-1810.
57. Jiang W J. 2008. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 373:341-344.
58. Juan M E, Vinardell M P and Planas J M. 2002. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132:257-260.
59. Juan S H, Cheng T H, Lin H C, Chu Y L and Lee W S. 2005. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem Pharmacol 69:41-48.
60. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman E A, Caldwell S D, Napper A, Curtis R, DiStefano P S, Fields S, Bedalov A and Kennedy B K. 2005. Substrate-specific activation of sirtu-ins by resveratrol. J Biol Chem 280:17038-17045.
61. Kaga S, Zhan L, Matsumoto M and Maulik N. 2005. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 39:813-822.
62. Karlsson J, Emgard M, Brundin P and Burkitt M J. 2000. Trans-resveratrol protects embryonic mes-encephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. J Neurochem 75:141-150.
63. Kim H P, Ryter S W and Choi A M. 2006. CO as a cellular signaling molecule. Annu Rev Pharmacol Toxicol 46:411-449.
64. Kim Y A, Kim G Y, Park K Y and Choi Y H. 2007. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food 10:218-224.
65. Klinge C M, Blankenship K A, Risinger K E, Bhatnagar S, Noisin E L, Sumanasekera W K, Zhao L, Brey D M and Keynton R S. 2005. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 280:7460-7468.
66. Kopp P. 1998. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138:619-620.
67. Kundu J K, Shin Y K, Kim S H and Surh Y J. 2006. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27:1465-1474.
68. Kyungmin In J P, Heonyong Park. 2006. Resveratrol at High Doses Acts as an Apoptotic Inducer in Endothelial Cells. Cancer Res Treat 38:48-53.
69. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P and Auwerx J. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109-1122.
70. Lee K W and Lee H J. 2006. The roles of polyphenols in cancer chemoprevention. Biofactors 26:105-121.
71. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, Das D K and Tosaki A. 2008. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294:H859-866.
72. Malik G, Gorbounov N, Das S, Gurusamy N, Otani H, Maulik N, Goswami S and Das D K. 2006. Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway. Antioxid Redox Signal 8:2101-2109.
73. Marambaud P, Zhao H and Davies P. 2005. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280:37377-37382.
74. Milne J C, Lambert P D, Schenk S, Carney D P, Smith J J, Gagne D J, Jin L, Boss O, Perni R B, Vu C B, Bemis J E, Xie R, Disch J S, Ng P Y, Nunes J J, Lynch A V, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair D A, Olefsky J M, Jirousek M R, Elliott P J and Westphal C H. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716.
75. Minotti G and Aust S D. 1989. The role of iron in oxygen radical mediated lipid peroxidation. Chem Biol Interact 71:1-19.
76. Miura T, Muraoka S, Ikeda N, Watanabe M and Fujimoto Y. 2000. Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol 86:203-208.
77. Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J and Sunagawa K. 2008. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28:1263-1269.
78. Mnjoyan Z H and Fujise K. 2003. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun 311:546-552.
79. Mukherjee S, Lekli I, Gurusamy N, Bertelli A A and Das D K. 2009. Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med 46:573-578.
80. Muller W J, Sinn E, Pattengale P K, Wallace R and Leder P. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
81. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S and Carruba M O. 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310:314-317.
82. Olas B, Wachowicz B, Szewczuk J, Saluk-Juszczak J and Kaca W. 2001. The effect of resveratrol on the platelet secretory process induced by endotoxin and thrombin. Microbios 105:7-13.
83. Orsini F, Pelizzoni F, Verotta L, Aburjai T and Rogers C B. 1997. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J Nat Prod 60:1082-1087.
84. Ou H C, Chou F P, Sheen H M, Lin T M, Yang C H and Huey-Herng Sheu W. 2006. Resveratrol, a polyphenolic compound in red wine, protects against oxidized LDL-induced cytotoxicity in endothelial cells. Clin Chim Acta 364:196-204.
85. Park C E, Kim M J, Lee J H, Min B I, Bae H, Choe W, Kim S S and Ha J. 2007. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39:222-229.
86. Parker J A, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H and Neri C. 2005. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349-350.
87. Paul B, Masih I, Deopujari J and Charpentier C. 1999. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J Ethnopharmacol 68:71-76.
88. Pearson K J, Baur J A, Lewis K N, Peshkin L, Price N L, Labinskyy N, Swindell W R, Kamara D, Minor R K, Perez E, Jamieson H A, Zhang Y, Dunn S R, Sharma K, Pleshko N, Woollett L A, Csiszar A, Ikeno Y, Le Couteur D, Elliott P J, Becker K G, Navas P, Ingram D K, Wolf N S, Ungvari Z, Sinclair D A and de Cabo R. 2008. Resveratrol delays age-related deterioration and mimics tran-scriptional aspects of dietary restriction without extending life span. Cell Metab 8:157-168.
89. Penumathsa S V and Maulik N. 2009. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87:275-286.
90. Pirola L and Frojdo S. 2008. Resveratrol: one molecule, many targets. IUBMB Life 60:323-332.
91. Rice-Evans C and Burdon R. 1993. Free radical-lipid interactions and their pathological consequences. Prog Lipid Res 32:71-110.
92. Richard JL. 1987. [Coronary risk factors. The French paradox]. Arch Mal Coeur Vaiss 80 Spec No:17-21.
93. Sato M, Fraga C and Das D K. 2004. Induction of the expression of cardioprotective proteins after mild-to-moderate consumption of alcohol. Pathophysiology 10:139-145.
94. Sharma S, Chopra K, Kulkarni S K and Agrewala J N. 2007. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 147:155-163.
95. She Q B, Huang C, Zhang Y and Dong Z. 2002. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 33:244-250.
96. Shen M Y, Hsiao G, Liu C L, Fong T H, Lin K H, Chou D S and Sheu J R. 2007. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 139:475-485.
97. Signorelli P and Ghidoni R. 2005. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16:449-466.
98. Singh N P, Hegde V L, Hofseth L J, Nagarkatti M and Nagarkatti P. 2007. Resveratrol (trans-3,5,4'-tri-hydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72:1508-1521.
99. Soleas G J, Diamandis E P and Goldberg D M. 1997. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30:91-113.
100. Sotomatsu A, Nakano M and Hirai S. 1990. Phospholipid peroxidation induced by the catechol-Fe3+(Cu2+) complex: a possible mechanism of nigrostriatal cell damage. Arch Biochem Biophys 283:334-341.
101. Stewart J R and O'Brian C A. 2004. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22:107-117.
102. Su J L, Yang C Y, Zhao M, Kuo M L and Yen M L. 2007. Forkhead proteins are critical for bone mor-phogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 282:19385-19398.
103. Subbaramaiah K and Dannenberg A J. 2003. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102.
104. Sun C, Hu Y, Liu X, Wu T, Wang Y, He W and Wei W. 2006. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165:9-19.
105. Szende B, Tyihak E and Kiraly-Veghely Z. 2000. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32:88-92.
106. Terzibasi E, Valenzano D R and Cellerino A. 2007. The short-lived fish Nothobranchius furzeri as a new model system for aging studies. Exp Gerontol 42:81-89.
107. Thirunavukkarasu M, Penumathsa S V, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das D K and Maulik N. 2007. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43:720-729.
108. Trincheri N F, Nicotra G, Follo C, Castino R and Isidoro C. 2007. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 28:922-931.
109. van Ginkel P R, Sareen D, Subramanian L, Walker Q, Darjatmoko S R, Lindstrom M J, Kulkarni A, Albert D M and Polans A S. 2007. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 13:5162-5169.
110. Vastano B C, Chen Y, Zhu N, Ho C T, Zhou Z and Rosen R T. 2000. Isolation and identification of stil-benes in two varieties of Polygonum cuspidatum. J Agric Food Chem 48:253-256.
111. Wilson D M, 3rd and Barsky D. 2001. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 485:283-307.
112. Wilson T, Knight T J, Beitz D C, Lewis D S and Engen R L. 1996. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 59:PL15-21.
113. Xanthoudakis S and Curran T. 1992. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. Embo J 11:653-665.
114. Xi J, Wang H, Mueller R A, Norfleet E A and Xu Z. 2009. Mechanism for resveratrol-induced car-dioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mito-chondrial permeability transition pore. Eur J Pharmacol 604:111-116.
115. Yamazaki I and Piette L H. 1990. ESR spin-trapping studies on the reaction of Fe2+ ions with H2O2-reactive species in oxygen toxicity in biology. J Biol Chem 265:13589-13594.
116. Yen G C, Duh P D and Lin C W. 2003. Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 37:509-514.
117. Zhou H B, Yan Y, Sun Y N and Zhu J R. 2003. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol 9:408-411.
118. Zhuang H, Kim Y S, Koehler R C and Dore S. 2003. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci 993:276-286; discussion 287-278.